SCHEMBL3620152

SCHEMBL3620152

CCOC(=O)Cc1csc(NS(=O)(=O)c2ccc(Cl)cc2)n1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 8/20 1.00
MEN1 O00255 7/20 0.80
ALDH1A1 P00352 2/20 0.80
CYP2C9 P11712 2/20 0.80
CYP2C19 P33261 2/20 0.80
PKM P14618 1/20 0.78
POLB P06746 2/20 0.76
MAPT P10636 4/20 0.69
SMN1; SMN2 Q16637 2/20 0.69
GAA P10253 3/20 0.63
HPGD P15428 1/20 0.63
KDM4E B2RXH2 1/20 0.62
LMNA P02545 1/20 0.59
CYP1A2 P05177 1/20 0.59
CYP3A4 P08684 1/20 0.59
KCNH2 Q12809 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3617781 0.91 KMT2A (0.83) KMT2AMEN1ALDH1A1CYP2C9CYP2C19
SCHEMBL28756893 0.90 KMT2A (0.82) KMT2AMEN1ALDH1A1CYP2C9CYP2C19
SCHEMBL27630314 0.89 KMT2A (0.80) KMT2AMEN1ALDH1A1CYP2C9CYP2C19
SCHEMBL3619889 0.89 KMT2A (0.80) KMT2AMEN1ALDH1A1CYP2C9CYP2C19
SCHEMBL27650147 0.89 KMT2A (1.00) KMT2AMEN1ALDH1A1CYP2C9CYP2C19
SCHEMBL27630068 0.89 KMT2A (0.80) KMT2AMEN1ALDH1A1CYP2C9CYP2C19
SCHEMBL11363579 0.89 ALDH1A1 (1.00) KMT2AMEN1ALDH1A1CYP2C9CYP2C19
SCHEMBL27650007 0.88 PKM (1.00) KMT2AMEN1ALDH1A1CYP2C9CYP2C19
SCHEMBL4963670 0.88 KMT2A (0.78) KMT2AMEN1ALDH1A1CYP2C9CYP2C19
SCHEMBL27650009 0.87 KMT2A (0.77) KMT2AMEN1ALDH1A1CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100113435-A1 INHIBITORS OF 11-BETA-HYDROXY STERIOD DEHYDROGENASE TYPE 1 BIOVITRUM AB 2010-05-06 US claimed
US-7618961-B2 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2009-11-17 US claimed
CN-1812784-A New use i BIOVITRUM AB (SE) 2006-08-02 CN claimed
EP-1638553-A1 NEW USE I BIOVITRUM AB (SE) 2006-03-29 EP claimed
WO-2004112784-A1 NEW USE I BIOVITRUM AB (SE) 2004-12-29 WO claimed
US-20040224996-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2004-11-11 US claimed
US-20100113435-A1 INHIBITORS OF 11-BETA-HYDROXY STERIOD DEHYDROGENASE TYPE 1 BIOVITRUM AB 2010-05-06 US disclosed
US-7618961-B2 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2009-11-17 US disclosed
CN-1812784-A New use i BIOVITRUM AB (SE) 2006-08-02 CN disclosed
EP-1638553-A1 NEW USE I BIOVITRUM AB (SE) 2006-03-29 EP disclosed
WO-2004112784-A1 NEW USE I BIOVITRUM AB (SE) 2004-12-29 WO disclosed
US-20040224996-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2004-11-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040224996-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 HSD11B1, HSD17B1, HSD11B2 KMT2A 3300/4885MEN1 832/4885ALDH1A1 55/4885
US-20100113435-A1 INHIBITORS OF 11-BETA-HYDROXY STERIOD DEHYDROGENASE TYPE 1 HSD11B1, HSD17B1, HSD3B1 KMT2A 3769/4885MEN1 752/4885ALDH1A1 59/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.